Connor, Clark & Lunn Investment Management (CC&L)’s Fortress Biotech FBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,299	Closed	-$42.2K	–	1311
2022 Q4	$42.2K	Sell	4,299 -421	-9%	-$4.66K	﹤0.01%	1154
2022 Q3	$61K	Buy	4,720 +977	+26%	+$14.6K	﹤0.01%	1061
2022 Q2	$47K	Buy	3,743 +2,227	+147%	+$33K	﹤0.01%	1007
2022 Q1	$31K	Buy	1,516 +279	+23%	+$7.64K	﹤0.01%	1008
2021 Q4	$46K	Sell	1,237 -657	-35%	-$29.3K	﹤0.01%	1048
2021 Q3	$91K	Buy	+1,894	New	+$92.5K	﹤0.01%	986
2020 Q2	–	Sell	-1,107	Closed	-$31K	–	1068
2020 Q1	$31K	Buy	+1,107	New	+$36.7K	﹤0.01%	979
2015 Q4	–	Sell	-860	Closed	-$34K	–	827
2015 Q3	$34K	Sell	860 -1,313	-60%	-$61.4K	﹤0.01%	698
2015 Q2	$110K	Buy	+2,173	New	+$112K	﹤0.01%	588

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FBIO Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Fortress Biotech (FBIO) in Q1 2023, closing a stake of 4,299 shares — an estimated $42.2K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FBIO in Q2 2015 and held it in 9 quarters. The position peaked at $110K in Q2 2015. 54 funds tracked by Wall St. Rank hold FBIO as of Q1 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Fortress Biotech position as of Q1 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 4,299 Fortress Biotech shares in Q1 2023, an estimated $42.2K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Fortress Biotech in Q2 2015 and held it in 9 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Fortress Biotech position peaked at $110K in Q2 2015.
54 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.